In the 2014 focused guidelines update, the CCS recommends use of the CHADS 2 schema referring to the original Gage et al publication 3 (and thus implying use of a similar definition). Thus, patients with some risk factors already included within the CHA 2 DS 2 -VASc score would not have been included in the 2014 CCS guidelines. Indeed, it is very important to strictly define the precise criteria for providing points related to each component in risk stratification scoring systems, and we welcome a clarifying update from the CCS committee on this matter.
Notwithstanding this inconsistency/misinterpretation on definitions, Cairn et al. raises the concern that previous publications using the Danish nationwide registries showed different event rates relative to those we presented. However, the devil is in the detail. Different populations and inclusion criteria, study settings, definitions on outcomes and time frames may account for the variation in event rates seen in various studies (see Online Supplement for full details).
In an attempt to specify and fully describe our event rates challenged by Cairns et al., we are pleased to provide a stratified analysis of 987 patients with prior vascular disease. We defined the 'VASc' component as follows: prior myocardial infarction, prior peripheral artery disease, or aortic plaque, as we have done previously 4 . It is evident that all subgroups of prior vascular diseases carry a high one-year thromboembolic event rate, see Table 1 . Contrasting low risk CHA 2 DS 2 -VASc (that is, score 0 (male) or 1 (female)) as a reference population vs those with ≥1 additional stroke risk factors (ie. CHA 2 DS 2 -VASc score =1 (male) or =2 (females)) to express the hazard attributable to vascular disease resulted in a crude HR of 2.7 (95%CI 1.7-4.2). Although long follow-up times (i.e. 10 or 12 years) may provide interesting insights into very longterm outcomes in AF patients, caution is warranted as baseline assumptions (on comorbidity and medication use) can be violated
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
To conclude, we could perhaps suggest a very simplified risk stratification and thromboprophylaxis algorithm based on the approach recommended by the ESC and NICE guidelines (see Online Figure   S1 ). By assessing the CHA 2 DS 2 -VASc score it is possible to identify the truly low risk patients (0 (male) or 1 (female)), who do not need any antithrombotic therapy. Cairn et al. raises the concern that previous publications using the Danish nationwide registries showed different event rates relative to those we presented. However, the devil is in the detail. The AF is associated with atherosclerotic vascular disease 11 .
In a different report, also by Olesen et al. 12 , AF patients with prior vascular disease were studied. In this study peripheral artery disease was somewhat more strictly defined (i.e. leaving out atherosclerosis of the aorta (ICD10: I700)). Cairns 
In an attempt to specify and fully describe our event rates challenged by Cairns et al., we are pleased to provide a stratified analysis of 987 patients with prior vascular disease (as defined in our CCS analysis 1 and excluding patients with prior SE or left ventricular dysfunction), see Table 1 . It is evident that all subgroups of prior vascular diseases carry a high one-year thromboembolic event rate. Contrasting low risk CHA 2 DS 2 -VASc (that is, score 0 (male) or 1 (female)) as a reference population vs those with ≥1 additional stroke risk factors (ie. CHA 2 DS 2 -VASc score =1 (male) or =2 (females)) to express the hazard attributable to vascular disease resulted in a crude HR of 2.7 (95%CI 1.7-4.2).
Of note, the event rate for patients with MI was 1. To conclude, we could perhaps suggest a very simplified risk stratification and thromboprophylaxis algorithm [ Figure S1 ] based on the approach recommended by the ESC and NICE guidelines where the initial step is to identify the low risk patients with CHA 
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